WOLVES HAND (194A) Fundamentals 2026 — P/E 13.6x, Revenue Analysis | SniperIQ
WOLVES HAND (194A) is a JP-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥12.2B, trading at ¥1613.00 on the JPX. This SniperIQ fundamentals page covers WOLVES HAND's valuation (P/E 13.6x, P/B 3.6x), profitability (net margin 14.9%), revenue (¥5.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is WOLVES HAND's market cap?
WOLVES HAND (194A) has a market capitalization of approximately ¥12.2B, trading at ¥1613.00 on the JPX. Market cap moves with the live share price.
What is WOLVES HAND's P/E ratio?
WOLVES HAND's trailing twelve-month P/E ratio is 13.6x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is WOLVES HAND?
WOLVES HAND runs a net profit margin of 14.9%, a gross margin of 26.4%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does WOLVES HAND generate?
WOLVES HAND reported revenue of ¥5.5B for fiscal year 2025, with net income of ¥593M and earnings per share (EPS) of 79.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does WOLVES HAND pay a dividend?
WOLVES HAND does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is WOLVES HAND financially healthy?
WOLVES HAND carries a debt-to-equity ratio of 0.65x and a current ratio of 1.27x, with a market beta of 1.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is WOLVES HAND a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For WOLVES HAND (194A) the key facts are: market cap ¥12.2B, P/E 13.6x, revenue ¥5.5B, 52-week range 721-2900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track WOLVES HAND's full fundamentals live
Get WOLVES HAND's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.